Arrakis set out on a clear mission to open new territories of medicine by creating a pioneering class of genetic medicines: RNA-targeted small molecules (rSMs). Today, our progress has changed the landscape and defined new rules for targeting RNA. We are at a pivotal turning point for rSMs. With a productive and scalable platform and a growing pipeline, we are approaching our destination: patients.